Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy

Novartis, which already has experience with RNA interference therapies, is now turning to this modality as a potential way to treat Parkinson’s disease. The pharmaceutical giant is licensing rights to an Arrowhead Pharmaceuticals RNAi therapy designed to inhibit production of alpha synuclein, a protein associated with Parkinson’s progression. The post Novartis Tries Again in Parkinson’s,…

Read More

Workload Up, Payment Down: The Growing Strain on Independent Practices

Physicians are facing rising workloads, shrinking support staff and declining reimbursement — resulting in a burnout crisis and threatening the sustainability of independent practices. Experts say urgent Medicare payment reforms are needed to prevent further consolidation, as well as preserve access to care. The post Workload Up, Payment Down: The Growing Strain on Independent Practices…

Read More